Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07164313Phase 1Recruiting

A Study of ZW251 in Participants With Advanced Solid Tumors

Role: lead

NCT06555744Phase 1Active Not Recruiting

A Study of ZW191 in Participants With Solid Tumors

Role: lead

NCT05035836Phase 2Recruiting

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Role: collaborator

NCT06523803Phase 1Terminated

A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

Role: lead

NCT04513665Phase 2Completed

ZW25 in Women With Endometrial Cancers

Role: collaborator

NCT05615818Phase 3Recruiting

Personalized Medicine for Advanced Biliary Cancer Patients

Role: collaborator

NCT03821233Phase 1Completed

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Role: lead

All 7 trials loaded